FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366821708> ?p ?o ?g. }

• W4366821708 endingPage "2800" @default.
• W4366821708 startingPage "2784" @default.
• W4366821708 abstract "Recurrent Clostridioides difficile infection (rCDI) is common and associated with considerable clinical and economic consequences. REBYOTA™ (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevention of rCDI following antibiotic treatment for rCDI. We sought to evaluate cost-effectiveness of FMBL compared to standard of care (SOC) from a US third-party payer perspective among patients with one or more (≥ 1) recurrences.A Markov model with a lifetime time horizon was developed. The model population included adult patients who had ≥ 1 recurrence after a primary CDI episode and had completed ≥ 1 round of antibiotics, or had ≥ 2 severe CDI episodes resulting in hospitalization within the last year. The model consisted of six health states with an 8-week model cycle: rCDI, absence of CDI after recurrence, colectomy, ileostomy, ileostomy reversal, and death. Drug costs and rCDI-related medical costs were estimated in 2022 US dollars and discounted at 3% annually. Deterministic sensitivity analyses were performed.Compared to SOC, FMBL at $9000/course resulted in an incremental cost-effectiveness ratio (ICER) of $18,727 per quality-adjusted life year (QALY) gained. The incremental cost was $5336 (FMBL $79,236, SOC $73,900) and the incremental effectiveness was 0.285 QALYs (FMBL 10.346, SOC 10.061). The cumulative drug acquisition and administration costs for the FMBL and SOC arms were $24,245 and $16,876, while rCDI-related medical costs for FMBL and SOC were $54,991 and $57,024, respectively. The ICER in the subgroup of patients at first recurrence was $13,727 per QALY gained. FMBL remained cost-effective across all sensitivity analyses.FMBL was found to be cost-effective compared to SOC for the prevention of rCDI with more benefits among patients at first recurrence, with an ICER far below the payer ICER threshold of $100,000. Patients treated with FMBL experienced higher total QALYs and reduced healthcare resource utilization, including reduced hospitalizations." @default.
• W4366821708 created "2023-04-25" @default.
• W4366821708 creator A5012377810 @default.
• W4366821708 creator A5019925558 @default.
• W4366821708 creator A5021604960 @default.
• W4366821708 creator A5021946870 @default.
• W4366821708 creator A5037505677 @default.
• W4366821708 creator A5060516605 @default.
• W4366821708 creator A5067461808 @default.
• W4366821708 creator A5083228477 @default.
• W4366821708 creator A5084249121 @default.
• W4366821708 date "2023-04-24" @default.
• W4366821708 modified "2023-10-05" @default.
• W4366821708 title "Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA" @default.
• W4366821708 cites W12101965 @default.
• W4366821708 cites W1968256786 @default.
• W4366821708 cites W1978992971 @default.
• W4366821708 cites W2071054182 @default.
• W4366821708 cites W2076426711 @default.
• W4366821708 cites W2084303232 @default.
• W4366821708 cites W2144282350 @default.
• W4366821708 cites W2170239385 @default.
• W4366821708 cites W2346616014 @default.
• W4366821708 cites W2507144333 @default.
• W4366821708 cites W2551338034 @default.
• W4366821708 cites W2626143723 @default.
• W4366821708 cites W2766283594 @default.
• W4366821708 cites W2788853459 @default.
• W4366821708 cites W2790379948 @default.
• W4366821708 cites W2802681502 @default.
• W4366821708 cites W2810428278 @default.
• W4366821708 cites W2883566781 @default.
• W4366821708 cites W2900400020 @default.
• W4366821708 cites W2903693734 @default.
• W4366821708 cites W2938551112 @default.
• W4366821708 cites W3003519966 @default.
• W4366821708 cites W3120114463 @default.
• W4366821708 cites W3135814913 @default.
• W4366821708 cites W3175883958 @default.
• W4366821708 cites W4220914817 @default.
• W4366821708 cites W4220946700 @default.
• W4366821708 cites W4226059852 @default.
• W4366821708 cites W4307250618 @default.
• W4366821708 cites W4311289344 @default.
• W4366821708 cites W4318173853 @default.
• W4366821708 doi "https://doi.org/10.1007/s12325-023-02505-1" @default.
• W4366821708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37093359" @default.
• W4366821708 hasPublicationYear "2023" @default.
• W4366821708 type Work @default.
• W4366821708 citedByCount "3" @default.
• W4366821708 countsByYear W43668217082023 @default.
• W4366821708 crossrefType "journal-article" @default.
• W4366821708 hasAuthorship W4366821708A5012377810 @default.
• W4366821708 hasAuthorship W4366821708A5019925558 @default.
• W4366821708 hasAuthorship W4366821708A5021604960 @default.
• W4366821708 hasAuthorship W4366821708A5021946870 @default.
• W4366821708 hasAuthorship W4366821708A5037505677 @default.
• W4366821708 hasAuthorship W4366821708A5060516605 @default.
• W4366821708 hasAuthorship W4366821708A5067461808 @default.
• W4366821708 hasAuthorship W4366821708A5083228477 @default.
• W4366821708 hasAuthorship W4366821708A5084249121 @default.
• W4366821708 hasBestOaLocation W43668217081 @default.
• W4366821708 hasConcept C112930515 @default.
• W4366821708 hasConcept C121608353 @default.
• W4366821708 hasConcept C126322002 @default.
• W4366821708 hasConcept C137923570 @default.
• W4366821708 hasConcept C2776667177 @default.
• W4366821708 hasConcept C2778980435 @default.
• W4366821708 hasConcept C2779489039 @default.
• W4366821708 hasConcept C2779900020 @default.
• W4366821708 hasConcept C2781342628 @default.
• W4366821708 hasConcept C2910067853 @default.
• W4366821708 hasConcept C2994496256 @default.
• W4366821708 hasConcept C3019080777 @default.
• W4366821708 hasConcept C501593827 @default.
• W4366821708 hasConcept C523546767 @default.
• W4366821708 hasConcept C526805850 @default.
• W4366821708 hasConcept C54355233 @default.
• W4366821708 hasConcept C64332521 @default.
• W4366821708 hasConcept C71924100 @default.
• W4366821708 hasConcept C86803240 @default.
• W4366821708 hasConcept C89423630 @default.
• W4366821708 hasConceptScore W4366821708C112930515 @default.
• W4366821708 hasConceptScore W4366821708C121608353 @default.
• W4366821708 hasConceptScore W4366821708C126322002 @default.
• W4366821708 hasConceptScore W4366821708C137923570 @default.
• W4366821708 hasConceptScore W4366821708C2776667177 @default.
• W4366821708 hasConceptScore W4366821708C2778980435 @default.
• W4366821708 hasConceptScore W4366821708C2779489039 @default.
• W4366821708 hasConceptScore W4366821708C2779900020 @default.
• W4366821708 hasConceptScore W4366821708C2781342628 @default.
• W4366821708 hasConceptScore W4366821708C2910067853 @default.
• W4366821708 hasConceptScore W4366821708C2994496256 @default.
• W4366821708 hasConceptScore W4366821708C3019080777 @default.
• W4366821708 hasConceptScore W4366821708C501593827 @default.
• W4366821708 hasConceptScore W4366821708C523546767 @default.
• W4366821708 hasConceptScore W4366821708C526805850 @default.
• W4366821708 hasConceptScore W4366821708C54355233 @default.

• next